drugset / Trial / NCT01965808

A Study of LY2157299 in Healthy Participants

NCT01965808

Phase 1 Completed 16 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelBasic science

Summary

Participants in this study will receive two oral doses of 150 milligram (mg) LY2157299 taken at least 4 days apart. One dose will be given without food. One dose will be given with a high fat meal. The study will evaluate the effect of a high fat meal on how much of the drug gets into the blood stream. Side effects will be documented. This study will last approximately 15 days not including screening. Screening is required within 30 days prior to the start of the study.

Timeline

Start
2013-10
Primary completion
2013-11
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Galunisertib Small molecule 150 mg Oral

Indications

No indication recorded.